Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Announces New Multispecific Antibody Collaboration with Merck

Business Wire July 8, 2020

Zymeworks Announces Corporate Update Webcast and Conference Call

Business Wire June 30, 2020

Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

Business Wire May 28, 2020

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Business Wire May 8, 2020

Zymeworks Reports 2020 First Quarter Financial Results

Business Wire May 7, 2020

Ancient Medicine Could Trigger New Treatments In Biotech

Livemoney May 7, 2020

5 Biotech Companies To Follow In 2020

Livemoney May 5, 2020

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Business Wire April 1, 2020

Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors

Business Wire March 16, 2020

Zymeworks Reports 2019 Year-End Financial Results

Business Wire March 2, 2020

Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference

Business Wire February 24, 2020

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

Business Wire January 27, 2020

Zymeworks Announces Pricing of $279.0 Million Public Offering

Business Wire January 22, 2020

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Business Wire January 21, 2020

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

Business Wire January 13, 2020

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

Business Wire January 12, 2020

Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

Business Wire January 7, 2020

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Business Wire November 22, 2019

Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

Business Wire November 18, 2019

Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

Business Wire November 5, 2019